Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 139, 2019 - Issue 10
Submit an article Journal homepage
434
Views
38
CrossRef citations to date
0
Altmetric
Oncology

Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study

Isaku OkamotoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan; Correspondence[email protected]
,
Hiroki SatoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
,
Takahito KondoDepartment of Otolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan;
,
Nobuyuki KoyamaDepartment of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan;
,
Chihiro FushimiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
,
Takuro OkadaDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
,
Kouki MiuraDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
,
Takashi MatsukiDepartment of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan;
,
Taku YamashitaDepartment of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan;
,
Go OmuraDepartment of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan
&
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
show all
Pages 918-925 | Received 02 May 2019, Accepted 12 Jul 2019, Published online: 28 Aug 2019

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Emily Clarke, Jesper Grau Eriksen & Sarah Barrett. (2021) The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis. Acta Oncologica 60:11, pages 1534-1542.
Read now
Ryuji Yasumatsu, Mioko Matsuo, Takahiro Wakasaki, Muneyuki Masuda, Toranoshin Takeuchi, Tomomi Manako, Rina Jiromaru, Ryutaro Uchi, Kazuki Hashimoto & Takashi Nakagawa. (2020) Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events. Acta Oto-Laryngologica 140:12, pages 1043-1048.
Read now

Articles from other publishers (36)

A. Thapa, A. Cowell, A. Peters, D.J. Noble, A. James, C. Lamb, D. Grose, S. Vohra, S. Schipani, K. Mactier, J. Mackenzie, D. Srinivasan, K. Laws, R. Moleron, P. Niblock, F.-Y. Soh, C. Paterson & C. Wilson. (2024) The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland. Clinical Oncology 36:5, pages 287-299.
Crossref
Osamu Fukuoka, Yuki Saito, Toshiyuki Mukai, Takaaki Hayashi, Koji Yamamura, Toshihiko Sakai, Kenya Kobayashi, Ken Akashi, Masafumi Yoshida, Mizuo Ando & Tatsuya Yamasoba. (2023) Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer. The Laryngoscope 134:1, pages 228-235.
Crossref
Toshimitsu Tanaka, Keisuke Miwa, Yasutaka Shimotsuura, Sachiko Nagasu, Hirona Shigyou, Keisuke Hirota, Shunji Koya, Yoshito Akagi & Takumi Kawaguchi. (2023) High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy. Journal of Gastroenterology and Hepatology 38:10, pages 1760-1767.
Crossref
Yue (Jennifer) Du, Rui Fu, Justin T. Levinsky, Pabiththa Kamalraj, Kelvin K. W. Chan, Ambica Parmar, Antoine Eskander & Martin Smoragiewicz. (2023) Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience. Current Oncology 30:10, pages 8928-8935.
Crossref
Kazuma Aoki, Takao Hamamoto, Nobuyuki Chikuie, Takashi Kono, Takayuki Taruya, Takashi Ishino, Tsutomu Ueda & Sachio Takeno. (2023) Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer. Auris Nasus Larynx 50:2, pages 309-313.
Crossref
Nanae Kaneta, Takashi Matsuki, Shunsuke Miyamoto & Taku Yamashita. (2023) A case of recurrent and metastatic laryngeal carcinoma with successful continuation of pembrolizumab therapy while controlling arthritisPembrolizumabによる関節炎を制御しながら治療継続できた再発転移喉頭癌の1例. Toukeibu Gan 49:3, pages 278-282.
Crossref
一朗 近松. (2022) 頭頸部癌治療の最前線. Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 125:9, pages 1409-1413.
Crossref
Isaku Okamoto, Takuro Okada, Kunihiko Tokashiki & Kiyoaki Tsukahara. (2022) Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers 14:18, pages 4413.
Crossref
Hae Reong Kim, MinDong Sung, Ji Ae Park, Kyeongseob Jeong, Ho Heon Kim, Suehyun LeeYu Rang Park. (2022) Analyzing adverse drug reaction using statistical and machine learning methods. Medicine 101:25, pages e29387.
Crossref
Miwako Someya, Takahito Kondo, Akira Okimura, Munehide Nakatsugawa, Mitsuru Okubo, Daisuke Yunaiyama, Atsuo Takeda, Takuma Kishida, Shigekazu Yoshida, Minami Yonekura, Yasuo Ogawa & Kiyoaki Tsukahara. (2022) Tracheobronchial chondritis as an immune-related adverse event occurring during the administration of nivolumab for recurrent hypopharyngeal squamous cell carcinoma. Ear, Nose & Throat Journal, pages 014556132210819.
Crossref
Isaku Okamoto, Kiyoaki Tsukahara & Hiroki Sato. (2022) Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. Scientific Reports 12:1.
Crossref
Yoshiaki Yura & Masakazu Hamada. (2022) Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. Cancers 14:3, pages 792.
Crossref
Akihiro Homma, Hirokazu KanekoToshimitsu Endo. (2022) Real world evidence of nivolumab in Japanese patients with head and neck cancer日本人頭頸部癌患者に対するニボルマブのリアルワールドデータ. Toukeibu Gan 48:1, pages 1-6.
Crossref
Makoto Tahara, Naomi Kiyota, Ken-ichi Nibu, Ayumi Akamatsu, Tomohiro Hoshino & Ryuichi Hayashi. (2021) Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. International Journal of Clinical Oncology 26:9, pages 1619-1627.
Crossref
Li Zhong, Qing Wu, Fuchun Chen, Junjin Liu & Xianhe Xie. (2021) Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunology, Immunotherapy 70:9, pages 2559-2576.
Crossref
Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura, Shinya Ozaki, Taijiro Ozawa, Ikuma Harata, Nobukazu Tanaka, Shinichiro Maseki, Hiroshi Tsuge, Sae Imaizumi, Shoji Mitsuya, Kazuho Moribe, Shinichi Esaki & Shinichi Iwasaki. (2021) Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. Scientific Reports 11:1.
Crossref
Takahito Kondo, Munehide Nakatsugawa, Mitsuru Okubo, Hironori Nakamura, Daisuke Yunaiyama, Midori Wakiya, Atsuo Takeda, Naiue Kikawada, Takuma Kishida, Miwako Someya, Shigekazu Yoshida, Yasuo Ogawa & Kiyoaki Tsukahara. (2021) Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation. Ear, Nose & Throat Journal, pages 014556132110310.
Crossref
Shin Kariya, Yasushi Shimizu, Nobuhiro Hanai, Ryuji Yasumatsu, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Masafumi Yoshida, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Shuji Yonekura, Takahiro Asakage, Akinori Fujiwara, Takayuki Yamada & Akihiro Homma. (2021) Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. International Journal of Clinical Oncology 26:6, pages 1049-1056.
Crossref
Yong Fan, Wenhui Xie, Hong Huang, Yunxia Wang, Guangtao Li, Yan Geng, Yanjie Hao & Zhuoli Zhang. (2021) Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Frontiers in Oncology 11.
Crossref
Tatsuya Ito, Hiroki Sato, Takahiro Tsujikawa, Hideaki Hirai, Isaku Okamoto, Keitaro Miyake, Toshitaka Nagao & Kiyoaki Tsukahara. (2021) Neck dissection prolongs survival in patient with stage IVC hypopharyngeal carcinoma with mixed responses to nivolumab. Auris Nasus Larynx 48:2, pages 322-326.
Crossref
Ifigenia Vasiliadou, Omar Breik, Holly Baker, Isla Leslie, Van Ren Sim, Gemma Hegarty, Andriana Michaelidou, Kannon Nathan, Andrew Hartley, James Good, Paul Sanghera, Charles Fong, Teresa Guerrero Urbano, Mary Lei, Imran Petkar, Miguel Reis Ferreira, Chris Nutting, Kee Howe Wong, Kate Newbold, Kevin Harrington, Shree Bhide & Anthony Kong. (2021) Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers 13:6, pages 1413.
Crossref
Nobuhiro Hanai, Yasushi Shimizu, Shin Kariya, Ryuji Yasumatsu, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Masafumi Yoshida, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Daiju Sakurai, Takahiro Asakage, Issei Doi, Takayuki Yamada & Akihiro Homma. (2020) Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. International Journal of Clinical Oncology 26:3, pages 494-506.
Crossref
Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Ryutaro Uchi, Rina Jiromaru, Kuniaki Sato, Tomomi Manako & Takashi Nakagawa. (2021) Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab. Oral Oncology 113, pages 105129.
Crossref
Koichiro Kato, Akihisa Horie, Yoshihiro Oohashi, Chieko Masuda, Yuta Kishi, Kenichi Kumagai & Yoshiki Hamada. (2021) A case of lower gingival squamous cell carcinoma showing complete response after the multidisciplinary therapy including Nivolumabニボルマブを含む集学的治療が著効した下顎歯肉扁平上皮癌の1例. Journal of Japanese Society of Oral Oncology 33:2, pages 47-54.
Crossref
Hyera Kim, Minsuk Kwon, Binnari Kim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park & Myung-Ju Ahn. (2020) Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. BMC Cancer 20:1.
Crossref
Takahito Kondo, Isaku Okamoto, Hiroki Sato, Nobuyuki Koyama, Chihiro Fushimi, Takuro Okada, Tatsuo Masubuchi, Kouki Miura, Takashi Matsuki, Taku Yamashita, Go Omura, Hideaki Takahashi & Kiyoaki Tsukahara. (2020) Age‐based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study. Asia-Pacific Journal of Clinical Oncology 16:6, pages 340-347.
Crossref
Panagiota Economopoulou, Ioannis Kotsantis, George Papaxoinis, Niki Gavrielatou, Maria Anastasiou, Anastasios Pantazopoulos, George Kavourakis, Stavros Gkolfinopoulos, Ioannis Panayiotides, Alexandros Delides & Amanda Psyrri. (2020) Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncology 111, pages 105013.
Crossref
Takashi Matsuki, Isaku Okamoto, Chihiro Fushimi, Hideaki Takahashi, Takuro Okada, Takahito Kondo, Hiroki Sato, Tatsuya Ito, Kunihiko Tokashiki, Kiyoaki Tsukahara, Kenji Hanyu, Tatsuo Masubuchi, Yuichiro Tada, Kouki Miura, Go Omura, Michi Sawabe, Daisuke Kawakita & Taku Yamashita. (2020) Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers 12:11, pages 3427.
Crossref
Chia‐Jui Yen, Naomi Kiyota, Nobuhiro Hanai, Shunji Takahashi, Tomoya Yokota, Shigemichi Iwae, Yasushi Shimizu, Ruey‐Long Hong, Masahiro Goto, Jin‐Hyoung Kang, Wing Sum Kenneth Li, Robert L. Ferris, Maura Gillison, Toshimitsu Endo, Vijayvel Jayaprakash & Makoto Tahara. (2020) Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141) . Head & Neck 42:10, pages 2852-2862.
Crossref
. (2020) PD-1阻害剤（頭頸部癌）. Nihon Kikan Shokudoka Gakkai Kaiho 71:4, pages 338-340.
Crossref
Akifumi Nakamura, Nobuyuki Kondo, Toru Nakamichi, Ayumi Kuroda, Masaki Hashimoto, Seiji Matsumoto, Takashi Yokoi, Kozo Kuribayashi, Takashi Kijima & Seiki Hasegawa. (2020) Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma. Japanese Journal of Clinical Oncology 50:8, pages 920-925.
Crossref
Isaku Okamoto, Hiroki Sato & Kiyoaki Tsukahara. (2020) Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx 47:4, pages 676-686.
Crossref
Isaku Okamoto, Hiroki Sato & Kiyoaki Tsukahara. (2020) DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx.
Crossref
Andrea Botticelli, Silvia Mezi, Giulia Pomati, Paolo Sciattella, Bruna Cerbelli, Michela Roberto, Giulia Mammone, Alessio Cirillo, Alessandra Cassano, Carmela Di Dio, Alessio Cortellini, Laura Pizzuti, Graziana Ronzino, Massimiliano Salati, Patrizia Vici, Antonella Polimeni, Marco Carlo Merlano, Marianna Nuti & Paolo Marchetti. (2020) The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines 8:2, pages 191.
Crossref
Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Masahiko Taura, Ryutaro Uchi & Takashi Nakagawa. (2020) Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncology 101, pages 104525.
Crossref
. (2019) Nivolumab. Reactions Weekly 1781:1, pages 272-272.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.